Carolina Strauss Estevez Gadelha
A5024292944- SARS-CoV-2 and COVID-19 Research
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- COVID-19 Clinical Research Studies
- Intramuscular injections and effects
- Heparin-Induced Thrombocytopenia and Thrombosis
- COVID-19 Impact on Reproduction
- Peripheral Neuropathies and Disorders
- Cancer Immunotherapy and Biomarkers
- Public Health in Brazil
- Dermatological and COVID-19 studies
- Pediatric health and respiratory diseases
- Autoimmune and Inflammatory Disorders Research
- Kawasaki Disease and Coronary Complications
- Respiratory viral infections research
- Vaccine Coverage and Hesitancy
- Systemic Lupus Erythematosus Research
Universidade Federal do Espírito Santo
2022-2024
Fundação Oswaldo Cruz
2022
Abstract Background Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. rheumatoid arthritis (RA) are at a high risk of severe outcomes, especially those under immunosuppression or associated comorbidities. However, few studies assessed safety vaccine in patients RA. Objective To evaluate vaccines against SARS-CoV-2 Methods This data from study “Safety and Efficacy on Vaccine Rheumatic Diseases,”...
<h3>Background:</h3> Phase III clinical trials have shown that COVID-19 vaccines are safe and effective in healthy children. There few studies children with juvenile autoimmune disease (AID). <h3>Objectives:</h3> The study aims to evaluate the immunogenicity safety of vaccine against Juvenile JAID real life. <h3>Methods:</h3> These data from "Safety efficacy on Vaccine Rheumatic Disease" - SAFER study, a Brazilian multicentric prospective phase IV AID. Immunogenicity adverse events (AE) were...
<h3>Background:</h3> Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. Individuals rheumatoid arthritis (RA) are at a high risk of severe outcomes, especially those under immunosuppression or comorbidities. In late 2022, SARS-CoV-2 omicron BA.5 sublineage accounted most sequenced viral genomes worldwide. Bivalent mRNA vaccines contain an ancestral strain component new coronavirus plus updated BA.4...
<h3>Background</h3> Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. rheumatoid arthritis (RA) are at a high risk of severe outcomes, especially those under immunosuppression or comorbidities associated. However, few studies in literature assessed safety and immunogenicity heterologous vaccine schedules patients RA. <h3>Objectives</h3> Evaluate two against SARS-CoV-2 <h3>Methods</h3> These data...
<h3>Background</h3> The ChAdOx1, Coronavac, BNT162B2 and Janssen vaccines are available for the primary booster immunization of immunosuppressed patients. However, there few studies in literature that assess immunogenicity safety different platforms COVID-19 patients with autoimmune diseases (AID). <h3>Objectives</h3> present study aims to evaluate through anti-spike IgG antibodies 28 days after dose heterologous boost groups compared homologous regimen vaccine against AID. <h3>Methods</h3>...
Abstract BACKGROUND Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. rheumatoid arthritis (RA) are at a high risk of severe outcomes, especially those under immunosuppression or comorbidities associated. However, few studies in literature assessed safety vaccine patients RA. OBJECTIVE Evaluate vaccines against SARS-CoV-2 METHODS These data from study “Safety and Efficacy on Vaccine Rheumatic...
A maioria dos casos pediátricos de COVID-19 é leve, porém graves podem ocorrer. No Brasil ocorreram mais 300 óbitos em crianças e adolescentes, no ano 2022, destacando a necessidade da vacinação. Este ensaio clínico avaliou imunogenicidade segurança vacinação 3 17 anos, com vacina inativada (Coronavac) contra o SARS-Cov2 grupo controle que recebeu BNT162b2 (Pfizer). Ensaio não inferioridade para avaliar (Coronavac/Butantan) braço randomizado, duplo-cego comparação imunizante BNT/Pfizer. Os...
A avaliação em crianças da vacina com plataforma de vírus inativado contra o SARS-Cov2 é especial interesse, por ser uma bem conhecida e aceita, além um recurso disponível produção nacional. Este ensaio clínico avaliou a imunogenicidade vacinação adolescentes, 3 17 anos, inativada (Coronavac) comparado adultos (18-49 anos) que receberam mesma vacina. Ensaio não inferioridade para avaliar (Coronavac/Butantan), braço aberto Coronavac. Todos duas doses 0,5 mL, intervalo 28 dias. Para...
Este é um relato da experiência de parcerias entre instituições públicas para o desenvolvimento pesquisas vacinas contra a COVID-19 implementadas no âmbito do Sistema Único Saúde (SUS), Estado Espírito Santo, com ênfase nas produção nacional, pela Fiocruz e Butantan. A decisão política estratégica dos gestores SUS investir em pesquisa inovação, aplicados nos projetos descritos nesse relato, está alinhada os aspectos políticos centrais Complexo Econômico Industrial (CEIS) que considera: 1)...